Extremely proud to announce that our NEOPREDICT-Lung study on neoadjuvant PD-1 and LAG-3 inhibition in resectable NSCLC is now online in Nature Medicine . Without any doubt one the highlights of my career so far.
nature.com/articles/s4159…
A justiça sentenciou meu marido a morte quando negou o tratamento a ele, mais conto a misericórdia de Deus e o apoio de todos vocês pra vencer essa batalha. #justiçaparaleonardo #direitoasaude #imunoterapia #nivolumab
44 months extended follow up of checkmate 9ER trial for advanced RCC . Maximum benifit in poor risk category. No OS benifit in favorable risk category. Intresting to note subsequent therapies in those who completed 2 years of Nivolumab. ESMO - Eur. Oncology Tom Powles
Check out our new story out in Nature Medicine today: a phase II study of nivolumab in dMMR/hypermutated gynecologic cancers together with my dear friend Claire Friedman MD . link.springer.com/article/10.103… brief summary (thread):
Dirk Verbeek Herman Steigstra Mnra zwangere vrouwen mogen dit niet gebruiken gebruiks aanwijzing OPDIVO NIVOLUMAB
Just out in ESMO open ESMO - Eur. Oncology With 44.0 months of median follow-up nivolumab/cabozantinib continues to outperform sunitinib in M1 clear cell RCC. The 3 VEGF/TKI combinations have more similarities than differences and track each other with longer follow up gbr01.safelinks.protection.outlook.com/?url=https%3A%…
❕Concurrent nivolumab and external beam radiation therapy for hepatocellular carcinoma with macrovascular invasion: A phase II study
🔓 #OpenAccess at 👉jhep-reports.eu/article/S2589-…
#LiverTwitter
#HepatocellularCarcinoma
#HCC
سلامات إن شاء الله
🟢 #سرطان_المرئ منه أنواع:
فيه نوع اسمه adenocarcinoma وممكن نعمل اختبار HER2 إذا موجب فممن استخدام مضادات الـHER2، وممكن نعمل اختبارات PDL1 و MSI إذا كانت موجبة نقدر نستخدم pembrolizumb
النوع الثاني اسمه squamous cell carcinoma ممكن نستخدم nivolumab
Jaroslaw Kuzdzal presents late breaking Presidential Abstract Recognition abstract: Surgical Outcomes With Perioperative Nivolumab (NIVO) in Patients (Pts) With Resectable NSCLC From the Phase 3 CheckMate 77T Study with Valerie Rusch of Memorial Sloan Kettering Cancer Center as commentator.
#AATS2024
Combined treatment using neoadjuvant nivolumab (arm A) or nivolumab-relatlimab (arm B) in tandem with chemoradiotherapy yielded favorable results. Nature Medicine Ronan Kelly ASCO AACR Conquer Cancer, the ASCO Foundation OncoAlert OncLive.com #esophagealcancer
bit.ly/3IVhzNN
Just out on ESMO Open
By our OncoAlert 🚨GU faculty Tom Powles Andrea Apolo, M.D. Toni Choueiri, MD and Team
Extended Follow Up from CheckMate 9ER
Report provides updated efficacy and safety data on Nivolumab plus Cabozantinib (NIVO + CABO) 🆚 sunitinib (SUN) for 1⃣st line treatment
🎧 Catch the latest episode of the Uromigos (@brian_rini, Tom Powles) with Daniel Goldstein MD on dosing issues and dosing changes in drugs such as #nivolumab and #pembrolizumab , as well as other immune checkpoint inhibitors.
👂 Listen Here: buff.ly/3W7fDcG
The Annals of Oncology article of the month ⭐️podcast 🎙️is now available!
EiC Tom Powles discusses with Amanda Psyrri the association of immune biomarkers and patient outcome in HNSCC treated with Nivolumab
Soundcloud: soundcloud.com/esmo-podcasts/…
Spotify: open.spotify.com/episode/1fz9FA…
Always lovely to speak with Graham Collins! Today he shared insights into hot topics in the field of #HodgkinLymphoma , including an update on the ANIMATE trial, the sequencing of nivolumab with other agents, and more!
We will be sharing interviews from #BSH2024 on
